Antifibrinolytic Agent

**Composition:**
Each tablet contains:
- Tranexamic acid 500mg

**Pharmacological action:**
- Tranexamic acid which has a strong inhibitory effect on the activation of plasminogen, i.e. the conversion of plasminogen to plasmin in the fibrinolytic system.

* Fibrinolysis may occur in the following conditions and situations:
  1. Prostatectomy and bladder surgery.
  2. Haematuria.
  4. Epistaxis.
  5. Menorrhagia.
  6. Ulcerative colitis.
  7. Conisation of the cervix.
  8. Dental extraction in patients with coagulopathies.

**Indications:**
Tranex tablet is antifibrinolytic agent indicated for:
- Haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis.

**Precautions:**
- Caution is needed when Tranex is used in patients with renal insufficiency and in massive haematuria from the upper urinary tract.
- Patients with a previous history of thromboembolic disease should not be given Tranex unless simultaneous treatment with anticoagulants can be given.

**Adverse effects:**
- Gastro-intestinal disturbances occur at an oral administration of 6g/day, Nausea, vomiting and diarrhea occur in (> 1/100).

**Pregnancy & Lactation:**
There are no adequate and well-controlled studies in pregnant women. Tranexamic acid passes into the breast milk, but an adverse effect on the child seems unlikely in the therapeutic dose range.

**Dosage and administration:**
The recommended standard dose is 2-3 tablets of 500mg 2-3 times daily, or as directed by the physician.

**Package:**
Box of 20 tablets in 2 strips.

Manufactured By:
Egyptian Group for Pharmaceutical Industries Co. Egypt